LoginSignup
UNC

Unicycive Therap

Stock
Stock
ISIN: US90466Y1038
Ticker: UNCY
US90466Y1038
UNCY

Price

Price

Frequently asked questions

What is Unicycive Therap's market capitalization?

The market capitalization of Unicycive Therap is $54.78M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Unicycive Therap?

Unicycive Therap's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.195. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Unicycive Therap's stock?

Currently, 5 analysts cover Unicycive Therap's stock, with a consensus target price of $5.30. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Unicycive Therap?

Unicycive Therap's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$29.15M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Unicycive Therap?

Unicycive Therap has a free cash flow of -$26.52M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Unicycive Therap's stock?

The 5-year beta for Unicycive Therap is 2.24. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Unicycive Therap have, and what sector and industry does it belong to?

Unicycive Therap employs approximately 14 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Unicycive Therap's shares?

The free float of Unicycive Therap is 97.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $54.78M

5Y beta

 2.24

EPS (TTM)

 -$0.195

Free Float

 97.44M

EBITDA (TTM)

 -$29.15M

Free Cashflow (TTM)

 -$26.52M

Pricing

52W span
$0.202$1.818

Analyst Ratings

The price target is $5.30 and the stock is covered by 5 analysts.

Buy

5

Hold

0

Sell

0

Information

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

14

Biotechnology & Drugs

Health Care

Identifier

ISIN

US90466Y1038

Primary Ticker

UNCY
Join the conversation
Sign upLogin